Nalfurafine
Nalfurafine is a pharmaceutical drug that acts as a kappa-opioid receptor agonist. It is primarily used in the treatment of pruritus (itching) associated with chronic kidney disease and liver disease. Nalfurafine is notable for its unique pharmacological profile, which allows it to alleviate itching without the typical side effects associated with other opioid medications, such as sedation and respiratory depression.
Pharmacology[edit | edit source]
Nalfurafine works by selectively activating the kappa-opioid receptors in the central and peripheral nervous systems. Unlike other opioids that primarily target the mu-opioid receptor, nalfurafine's selective action on kappa receptors helps to reduce the sensation of itching without causing significant euphoria or addiction potential. This makes it a valuable option for patients who require long-term management of pruritus.
Medical Uses[edit | edit source]
Nalfurafine is approved for use in several countries, including Japan and the United States, for the treatment of pruritus in patients undergoing hemodialysis or those with chronic liver disease. It is often prescribed when other treatments, such as antihistamines and corticosteroids, are ineffective.
Side Effects[edit | edit source]
Common side effects of nalfurafine include:
Serious side effects are rare but may include:
Mechanism of Action[edit | edit source]
Nalfurafine's mechanism of action involves the modulation of neurotransmitter release in the central nervous system. By binding to kappa-opioid receptors, it inhibits the release of substance P and other neuropeptides involved in the transmission of itch signals. This results in a reduction of the sensation of itching.
Development and Approval[edit | edit source]
Nalfurafine was developed by the Japanese pharmaceutical company Toray Industries. It was first approved for use in Japan in 2009 under the brand name Remitch and has since been approved in other countries for similar indications.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
-
Nalfurafine | |
---|---|
[[File:|frameless|220px|alt=|]] | |
INN | |
Drug class | |
Routes of administration | |
Pregnancy category | |
Bioavailability | |
Metabolism | |
Elimination half-life | |
Excretion | |
Legal status | |
CAS Number | |
PubChem | |
DrugBank | |
ChemSpider | |
KEGG |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD